Cargando…

Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial

This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.

Detalles Bibliográficos
Autores principales:	Cheng, Matthew, Fowler, Rob, Murthy, Srinivas, Pinto, Ruxandra, Sheehan, Nancy L., Tseng, Alice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425145/ https://www.ncbi.nlm.nih.gov/pubmed/36036936 http://dx.doi.org/10.1001/jamanetworkopen.2022.29236

Ejemplares similares

Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial
por: Lau, Vincent I., et al.
Publicado: (2022)

1366. Temporal changes in Demographics, Characteristics and Treatments for Patients enrolled in the Canadian Treatments for COVID-19 Trial
por: Mohsen, Samiha, et al.
Publicado: (2023)

The authors respond to “Concerns about subgroup analyses and reason for stopping remdesivir trial”
por: Murthy, Srinivas
Publicado: (2022)

Remdesivir: Kidney disorder : case report
Publicado: (2021)

Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys
por: Xu, Lin, et al.
Publicado: (2021)

Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
por: Lin, Kevin, et al.
Publicado: (2022)

Safety of Remdesivir in Patients With Acute Kidney Injury or CKD
por: Thakare, Sayali, et al.
Publicado: (2020)

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction
por: Ogawa, Akiko, et al.
Publicado: (2023)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir-related acute kidney injury in patients with COVID-19
Publicado: (2020)

Liver and kidney function in patients with Covid‐19 treated with remdesivir
por: van Laar, Sylvia A., et al.
Publicado: (2021)

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19
por: Buxeda, Anna, et al.
Publicado: (2021)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Length of remdesivir treatment in patients with severe COVID-19
por: Ippolito, Mariachiara, et al.
Publicado: (2021)

Is It Time to Revisit Remdesivir Use for Severe COVID-19?
por: Taggarsi, Dipali Anand
Publicado: (2022)

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
por: Rosas, Ivan O., et al.
Publicado: (2021)

Remdesivir: Renal dysfunction and liver dysfunction following off-label use: 2 case reports
Publicado: (2022)

Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
por: Al Bishawi, Ahmad, et al.
Publicado: (2022)

Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
por: Anderson, Michaela R., et al.
Publicado: (2020)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report
por: Khan, Shahkar, et al.
Publicado: (2022)

Remdesivir: Acute kidney injury, oxalosis and increased aminotransferase: case report
Publicado: (2022)

Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia()
por: Cacho, Judit, et al.
Publicado: (2022)

Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center
por: McCoy, Jennifer A., et al.
Publicado: (2020)

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
por: Goldman, Jason D., et al.
Publicado: (2020)

Remdesivir use in severe renal impairment: benefits outweigh risks
Publicado: (2021)

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
por: Gottlieb, Robert L., et al.
Publicado: (2021)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Severe COVID-19 Pneumonia in an Unvaccinated Female Treated With Remdesivir
por: Ortega, Kaylee, et al.
Publicado: (2022)

Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis
por: Geffin, Ryan, et al.
Publicado: (2023)

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
por: Burwick, Richard M, et al.
Publicado: (2020)

Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function
por: Seethapathy, Rituvanthikaa, et al.
Publicado: (2023)

Remdesivir: Infusion site reaction following extravasation of remdesivir: case report
Publicado: (2021)

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis
por: Peyko, Vincent, et al.
Publicado: (2020)

Remdesivir: Acute kidney injury and elevated ALT level: 2 case reports
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_deg99ccjcnfqe150h2aol9gvns